We are hiring fellows for a pilot initiative at @mskcancercenter.bsky.social – The Theory Group. The Group is centered around tumor-immune interactions and, post-AI, theoretical approaches that can unlock fundamental questions with translational impact. msk.wd108.myworkdayjobs.com/MSKCC_Career...

Congrats to MSK's most recent awards and appointments, including Dr. Joan Massagué for receiving the Kennedy Award from the Institut d’Estudis Nord-americans (IEN); Dr. Daniel Heller for being named a Gray Foundation Grant Recipient; and more: https://bit.ly/4wp853H

The FDA has approved zidesamtinib for advanced ROS1-positive non-small cell #lungcancer that stopped responding to other #ROS1 drugs. MSK thoracic medical oncologist Dr. Alexander Drilon led the clinical trial. Learn more: https://bit.ly/4q7Bluh

The FDA has approved zenocutuzumab for adults with advanced, inoperable, or metastatic cholangiocarcinoma driven by an NRG1 gene fusion. The approval is based on a trial led by MSK’s Dr. Alison Schram giving patients with limited treatment options a new choice. Learn more: https://bit.ly/4fGFXTf

Calling all fourth-year medical students interested in #RadOnc! 🩺 Join the Chief Residents from MSK for a virtual info session about MSK's Radiation Oncology Residency Program. Learn more about our training program, research opportunities, and resident life. Register: https://bit.ly/4vKnN9e

(1/2) Five years after her passing, the final study from the lab of the late MSK developmental biologist and department chair Dr. Kathryn Anderson has been published, revealing how a critical signaling molecule called WNT tells cells in the embryo what they will become.

MSK's Dr. Lydia Finley and researchers study #cellmetabolism, aka how cells convert nutrients into the various molecules that they need to function. By shedding new light on fundamental biology, the researchers aim to find new strategies that could work against cancer. https://bit.ly/4vwCNHE

(1/2) Scientists from MSK and @weillcornell.bsky.social found that a small subset of T cells, called stem T cells, are responsible for making new T cells and continuously replenishing them in chronic disease.

Join is for an inaugural two-day virtual symposium @mskcancercenter.bsky.social highlighting advances in surgical oncology, from perioperative care and minimally invasive approaches to complex emergencies, technology, workforce development, and health equity. Learn more: bit.ly/SurgOnc2026

Forum @cp-cellhostmicrobe.bsky.social Operationalizing microbiome ecology in cancer care www.cell.com/cell-host-mi... @mskcancercenter.bsky.social

Novel #immunotherapy approaches such as T cell-engager therapies, CD40 agonists, and HSV-TK gene therapy have shown early promise for the treatment of #ProstateCancer. Read the review from Drs. Dallos, Gaffney, and @mskcancercenter.bsky.social collaborators. 📖 🔗 https://go.nature.com/4vRA5x7

The FDA has granted full approval for an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. More about the clinical trials resulting in the drug’s approval, led by MSK's Dr. Sandra D’Angelo: https://bit.ly/4eVcTZ4

New research from MSK investigates how a natural antifungal compound produced by helpful gut bacteria might help protect vulnerable patients; finds that a protein “fingerprint” in blood could predict dangerous clots in cancer patients; and more: https://bit.ly/4vzMuFj

We're thrilled to welcome a new Associate Editor to Blood today! Dr. Omar Abdel-Wahab is the Evnin Family Chair of Molecular Pharmacology at @mskcancercenter.bsky.social where he also serves as Chair of the Molecular Pharmacology Program in the Sloan Kettering Institute. #NewEditor

LEF1 and niche-derived factors are identified as essential regulators of T cell stemness across chronic diseases @cellcellpress.bsky.social @mskcancercenter.bsky.social @dbetel.bsky.social et al www.cell.com/cell/fulltex...

New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #AI-driven drug discovery initiative. Learn more: https://bit.ly/4uZZDHb

New study alert: Roni Shouval & team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @mskcancercenter.bsky.social Read the study: https://bit.ly/4vYu0yL

Now in Cancer Discovery @aacrjournals.bsky.social: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-related Survival - by Justin Jee, @sawyerslabmskcc.bsky.social, Nikolaus Schultz, et al. doi.org/10.1158/2159... @mskcancercenter.bsky.social

MSK researchers are helping advance #MorPhiC, an international effort to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.

MSK scientists have uncovered a hidden role for RNA. Researchers led by MSK molecular and cell biologist @christinemayr.bsky.social found that RNA can act as a critical regulatory proteins, revealing a previously unknown function of RNA. Learn more: https://bit.ly/3QpBprx

mRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity @cellcellpress.bsky.social @mskcancercenter.bsky.social @christinemayr.bsky.social www.cell.com/cell/fulltex...

🎉 Congrats to MSK's most recent awards & appointments, including Dr. Yelena Janjigian, Dr. Samuel Cytryn, and Dr. Jeremy Tchack for being awarded funding by the Torrey Coast Foundation; Dr. Scott Lowe for receiving the 2026 Lotus Award; and more: www.mskcc.org/news-release...

📢 New Review Published in EXO! Title: Ferroptosis spreading through propagative signals By Drs. Saloni K. Hombalkar, Jyotirekha Das, and Michael Overholtzer from @mskcancercenter.bsky.social 🔗 Open access: sciexplor.com/exo/articles... #Ferroptosis #CellDeath #RedoxBiology

Missed some of the research presented by MSK experts at #ASCO26? We've rounded up selected highlights spanning sarcoma, liver cancer, lung cancer, prostate cancer, blood cancers, and more: https://bit.ly/3Qfyv8Q

Closing out strong, join MSK radiation oncologist Dr. Amy Xu at #ASCO26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations. 🕒 Tuesday, June 2 | 10:39 a.m. CDT Learn more: https://bit.ly/4x1m1ST

Coming up at #ASCO26: Join #melanoma medical oncologist Dr. Alexander Shoushtari for a presentation on how new tumor-infiltrating lymphocyte research can be translated into real benefit for patients. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 5:30 p.m. CDT Learn more: https://bit.ly/4nX5jjg

Join MSK's Dr. Michael Morris at #ASCO26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients w/ metastatic castration-resistant #prostatecancer previously treated with Lu-PSMA therapy. Learn more: meetings.asco.org/meetings/202...

Join MSK thoracic medical oncologist Dr. Jamie Chaft at #ASCO26 as she presents results from the phase III ALCHEMIST trial evaluating nivolumab after surgery and adjuvant chemotherapy in patients with non-small cell lung cancer. 🕒 Monday, June 1 | 1:15 p.m. CDT Learn more: https://bit.ly/3Q9i1Pw

Join MSK medical oncologist Dr. Darren Feldman at #ASCO26 for an education session on optimizing treatment for patients with poor-risk testicular cancer, including a discussion on the management of brain metastasis. 🕒 Monday, June 1 | 1:51 p.m. CDT Learn more: https://bit.ly/4uEc3VN

🚨 New findings presented at #ASCO26: An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC).